Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Friday: Gold Fields Limited (ADR) (NYSE:GFI), Penn West Petroleum Ltd (USA) (NYSE:PWE), Harmony Gold Mining Co. (ADR) (NYSE:HMY), Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

• Gold Fields Limited (ADR) (NYSE:GFI), with shares dwindled -4.75% is now trading at $4.41. The Stock is active as 2.61M shares changed hands versus its average volume of 4.58M shares.

• Penn West Petroleum Ltd (USA) (NYSE:PWE), with shares raised 3.31% is now trading at $1.56. The Stock is active as 2.65M shares changed hands versus its average volume of 6.39M shares.

• Harmony Gold Mining Co. (ADR) (NYSE:HMY) with shares enhanced 7.92% is now trading at $1.98. The Stock is active as 2.55M shares changed hands versus its average volume of 2.80M shares.

• Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with shares rose 5.34% is now trading at $4.24. The Stock is active as 2.17M shares changed hands versus its average volume of 1.54M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Gold Fields Ltd. (NYSE:GFI)

Gold Fields Ltd. (GFI), has price to sale ratio of 1.15, however, price to book ratio is 0.92. With recent incline, the year-to-date (YTD) performance reflected a -1.55% decline below last year. During the past month the stocks gain 9.36%, bringing three-month performance to 1.83% and six-month performance to 4.23%. The mean recommendation of analysts for this stock is 3.50. (where 1=Buy, 5=Sale).

Gold Fields Limited is engaged in the attainment, exploration, development, and production of gold properties. It also explores for copper. The company holds interests in eight operating mines in Australia, Ghana, Peru, and South Africa. It also has interests in the Granny Smith, Lawlers, and Darlot gold mines in Western Australia. The company has total gold mineral reserves of about 49 million ounces and mineral resources of about 113 million ounces. Gold Fields Limited was founded in 1968 and is based in Sandton, South Africa.

Penn West Petroleum Ltd. (NYSE:PWE)

Formerly on March 12, Penn West Petroleum Ltd. (PWE), declared that it has filed with Canadian securities regulatory authorities its audited Merged Financial Statements for the year ended December 31, 2014 and related Administration’s discussion and Analysis. Penn West has also filed its Annual Information Form for the year ended December 31, 2014 , which comprises the disclosure and reports regarding reserves data and other oil and gas information required following National Instrument 51-101. Penn West’s Annual Report on Form 40-F for the year ended December 31, 2014 will be filed with the U.S. Securities and Exchange Commission later that day.

Penn West Petroleum Ltd. explores for, develops, and produces oil and natural gas properties in western Canada. The corporation’s properties are located in Alberta, British Columbia, Saskatchewan, Manitoba, and the Northwest Territories, Canada.

Harmony Gold Mining Company Limited (NYSE:HMY)

Harmony Gold Mining Corporation Limited (HMY), has volatility for the week is 5.89%, while for the month remained 4.86%.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed -0.33 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 55.00% and Annual EPS growth for the past 5 years is considered as -20.30%.

The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).

Harmony Gold Mining Corporation Limited is engaged in the exploration and mining of gold in South Africa and Papua New Guinea. The corporation also explores for silver, copper, and molybdenum.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals, Inc. (SGYP), stated its financial results and business update for the fourth quarter and the year ended December 31, 2014.

Financial Results:

• The company’s cash, cash equivalents and accessible-for-sale securities balance as of December 31, 2014 was $196.4 million, as contrast to $68.2 million on December 31, 2013.
• Net cash offered by financing activities was $217.1 million during the year ended December 31, 2014, as contrast to $89.2 million offered during the year ended December 31, 2013.
• Net cash used in operating activities during the year ended December 31, 2014 was $89.1 million as contrast to $52.6 million of cash used in operating activities during the twelve months ended December 31, 2013.
• Net loss for the year ended December 31, 2014 was $95.7 million or $1.02 per share as contrast to $62.1 million or $0.73 per share for the year ended December 31, 2013.
• Net loss for the quarter ended December 31, 2014 was $30.6 million, or $0.32 per share, as contrast to $19.9 million or $0.22 per share, for the quarter ended December 31, 2013.
• Interest expense on the Notes totaled $2.5 million, or $0.03 per share, during the quarter ended December 31, 2014, whereas the company had no such expense during the quarter ended December 31, 2013.

Synergy is a biopharmaceutical corporation focused on the development of novel therapies to treat gastrointestinal (GI) diseases and disorders. The corporation’s proprietary platform technology is based on the naturally occurring human GI peptide – uroguanylin - a key to normal GI physiology.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.